Publication detail

Shedding light on triple-negative breast cancer with Trop2-targeted antibody-drug conjugates

JABBARZADEH KABOLI, P. SHABANI, S. SHARMA, S. PARTOVI NASR, M. YAMAGUCHI, H. HUNG, M.

Original Title

Shedding light on triple-negative breast cancer with Trop2-targeted antibody-drug conjugates

Type

journal article in Web of Science

Language

English

Original Abstract

Triple-negative breast cancer (TNBC) is well-known as the most aggressive subtype of breast cancer. Because TNBC does not express Her2, estrogen receptor, and progesterone receptors, there had been no effective U.S. Food and Drug Administration-approved targeted therapy for it until PARP inhibitors and two PD-1/PD-L1 monoclonal antibodies were approved for treatment of TNBC. Most recently, an antibody-drug conjugate (ADC), called sacituzumab govitecan (SG), was approved for the treatment of TNBC patients previously received chemotherapy with advanced disease. SG consists of an anti-trophoblast cell-surface antigen 2 (Trop2) antibody conjugated with a topoisomerase I inhibitor, SN-38, which is diffused out of the targeted Trop2 positive cancer cells and induces the bystander killing effect on surrounding cells regardless of their Trop2 expression status. In the Phase III clinical trial, TNBC patients treated with SG showed significantly longer progression-free and overall survival compared to those who were received chemotherapy. In the present review, we summarized the cellular function and signaling of Trop2, the mechanism of action of SG, and the clinical trials of SG that led to its quick approval for TNBC. In addition, we introduced the current ongoing clinical trials of SG as well as another Trop2 ADC, which has potential to overcome some disadvantages of SG.

Keywords

Triple-negative breast cancer, sacituzumab govitecan, Trop2, SN-38, antibody-drug conjugates

Authors

JABBARZADEH KABOLI, P.; SHABANI, S.; SHARMA, S.; PARTOVI NASR, M.; YAMAGUCHI, H.; HUNG, M.

Released

12. 4. 2022

Publisher

E-CENTURY PUBLISHING CORP

ISBN

2156-6976

Periodical

American Journal of Cancer Research

Year of study

12

Number

4

State

unknown

Pages from

1671

Pages to

1685

Pages count

15

URL

https://pubmed.ncbi.nlm.nih.gov/35530278/

BibTex

@article{BUT183042,
  author="Parham {Jabbarzadeh Kaboli} and Shima {Shabani} and Sagar {Sharma} and Minoo {Partovi Nasr} and Hirohito {Yamaguchi} and Mien-Chie {Hung}",
  title="Shedding light on triple-negative breast cancer with Trop2-targeted antibody-drug conjugates",
  journal="American Journal of Cancer Research",
  year="2022",
  volume="12",
  number="4",
  pages="15",
  issn="2156-6976",
  url="https://pubmed.ncbi.nlm.nih.gov/35530278/"
}